Screener
Arcus Biosciences RCUS License and development services — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| License and development services (Includes $8, $152, $18 and $172 from a related party) | $16 | $152 | $28 | $172 |
| Other collaboration(Includes $25, $8, $30 and $16 from a related party) | 25 | 8 | 30 | 16 |
| Total revenues | 41 | 160 | 58 | 188 |
| Operating expenses: | ||||
| Research and development (Includes $2, $11, $2 and $6 from a related party) | 113 | 139 | 235 | 261 |
| General and administrative(Includes $—, $2, $— and $2 from a related party) | 24 | 29 | 53 | 57 |
| Total operating expenses | 137 | 168 | 288 | 318 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's license and development services — total revenues?
- Arcus Biosciences (RCUS) reported license and development services — total revenues of $16M in Q2 2026.
- How has Arcus Biosciences's license and development services — total revenues changed year-over-year?
- Arcus Biosciences's license and development services — total revenues decreased by 89.5% year-over-year, from $152M to $16M.
- What does license and development services — total revenues mean?
- This metric represents the total revenue recognized from licensing intellectual property and providing research and development services to strategic partners. It reflects the company's ability to monetize its clinical-stage pipeline through collaborative agreements and milestone-based payments. This revenue stream is a critical indicator of the commercial validation of the company's proprietary drug candidates.
Ask your AI about Arcus Biosciences's license and development services — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude